<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00568477</url>
  </required_header>
  <id_info>
    <org_study_id>VAL-518-HEE-0200-S</org_study_id>
    <secondary_id>EudraCT-number: 2006-006137-41</secondary_id>
    <nct_id>NCT00568477</nct_id>
  </id_info>
  <brief_title>Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation</brief_title>
  <acronym>Rituximab 2006</acronym>
  <official_title>Prospective, Randomized, Open, 2-arm National Multi-center Study to Evaluate the Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Humboldt-Universität zu Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Erlangen-Nürnberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Transplantationszentrum Köln-Merheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Martin-Luther-Universität Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the benefit of rituximab in patients with CAN with histologically proven C4d
      deposits and/or plasma cell and/or B-Lymphocyte (CD20+ cells) infiltration of their grafts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized, open, 2-arm, national multi-center study to evaluate
      the value of rituximab in humoral chronic rejection after renal transplantation in
      approximately 150-200 patients (75-100 patients each group).

      All biopsies will be analysed by Prof. Groene (Heidelberg) and the results immediately
      communicated to the central managing unit (Munich). Upon receipt, patients with biopsy proven
      CAN with C4d+ and/or plasma-cells and/or B-lymphocytes within the last 4 weeks before
      inclusion (centrally confirmed), fulfilling the inclusion/exclusion criteria, will be
      randomized 1:1 into one of the 2 groups:

      Arm 1: Treatment with rituximab Arm 2: Treatment without rituximab Recruitment will last for
      approximately one year. All patients will be treated with baseline medication of Tacrolimus,
      MMF, steroids (optional, with same dose as given before study entry) and ACE-inhibitor or
      AT1-receptor-antagonist. A single dose of 100 mg Methylprednisolone i.v. will be given at
      baseline (day 0) in both groups (in the rituximab group 30 min before start of the rituximab
      infusion).

      Each patient will be followed for 1 year within protocol, with study visits at 1,3,7 and 14
      days (rituximab group), 3, 6 and 12 months followed by a follow-up period of 1 year with a
      study visit at 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lacking recruitment
  </why_stopped>
  <start_date>December 2007</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary objective: To evaluate the benefit of Rituximab in patients with CAN with histologically proven C4d deposits and/or B-Lymphocyte (CD20+ cells) infiltration of their grafts. Secondary objectives: Renal function at 1 year</measure>
    <time_frame>Graft survival at 1 and 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function at 1 year</measure>
    <time_frame>Graft survival at 1 and 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Grafting</condition>
  <condition>Renal Transplantation</condition>
  <condition>Transplantation, Kidney</condition>
  <condition>Chronic Allograft Nephropathy</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Treatment without rituximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MabThera</intervention_name>
    <description>Rituximab (MabThera):
375 mg/m² as IV infusions over &gt;=6h each at time point 0 and 2 weeks. Initial infusion rate of 50 mg/h, stepwise rise is possible after 30 minutes</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal allograft recipients at least 1 year after transplantation with GFR &gt; 25 ml/min
             x 1,73m2 (MDRD)

          -  Single organ recipients of renal allograft

          -  Patients who have provided informed consent

          -  Patients who are &gt;= 18 years of age

          -  Patients who have biopsy proven CAN with C4d+ deposits and/or plasma-cells and/or
             B-lymphocytes within the last 4 weeks before inclusion

          -  Patients who are treated with ACE/AT1 Blocker more than 1 week before inclusion

        Exclusion Criteria:

          -  Patients who suffer from HIV infection

          -  Patients with a history of Hepatitis B

          -  Patients with Hepatitis C (active/chronic)

          -  Patients who have a contraindication for the use of rituximab, such as leukopenia or
             experienced infusion-related adverse events to former antibody treatment

          -  Patients who showed signs of acute cellular rejection in the biopsy

          -  Patient has a malignancy or history of malignancy within the last 5 years, except
             non-metastatic basal or squamous cell carcinoma of the skin that has been treated
             successfully.

          -  Patient has a systemic infection requiring treatment.

          -  Female patients who are pregnant or lactating

          -  Patients who have any form of substance abuse, psychological illness or any other
             condition, which, in the opinion of the investigator, may interfere with the patient's
             ability to understand the requirements of the study.

          -  Patients who have a proteinuria &gt;4g/24h

          -  Patient is unlikely to comply with the visits scheduled in the protocol.

          -  Patient is simultaneously participating in another investigational drug study or has
             participated in such study within 28 days before entry in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwe Heemann, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technical University of Munich, Klinikum rechts der Isar; Münchner Studienzentrum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Technical University of Munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2007</study_first_submitted>
  <study_first_submitted_qc>December 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <last_update_submitted>September 30, 2009</last_update_submitted>
  <last_update_submitted_qc>September 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Univ.-Prof. Dr. med. Dr. h.c. Uwe Heemann</name_title>
    <organization>Technical University of Munich, Klinikum rechts der Isar</organization>
  </responsible_party>
  <keyword>Rituximab, Heemannn</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

